UA79749C2
(en)
|
1996-10-18 |
2007-07-25 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
|
US7094770B2
(en)
|
2000-04-13 |
2006-08-22 |
Pharmasset, Ltd. |
3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
EA200601591A1
(ru)
|
2000-05-26 |
2007-02-27 |
Айденикс (Кайман) Лимитед |
Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
RS50236B
(sr)
*
|
2001-01-22 |
2009-07-15 |
Merck & Co.Inc., |
Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze
|
US8481712B2
(en)
*
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
EP1423522A2
(fr)
|
2001-01-23 |
2004-06-02 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Replicons du virus de l'hepatite c et cellules renforcees pour des replicons
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
GB0114286D0
(en)
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
WO2003026589A2
(fr)
*
|
2001-09-28 |
2003-04-03 |
Idenix (Cayman) Limited |
Procedes et compositions pour le traitement du virus de l'hepatite c au moyen de nucleosides modifies en 4'
|
AU2002353164A1
(en)
*
|
2001-12-17 |
2003-06-30 |
Ribapharm Inc. |
Unusual nucleoside libraries, compounds, and preferred uses as antiviral and anticancer agents
|
WO2003062256A1
(fr)
*
|
2002-01-17 |
2003-07-31 |
Ribapharm Inc. |
Analogues d'adenosine 2'-beta-modifiee-6-substituee et leur utilisation en tant qu'agents antiviraux
|
US20070032448A1
(en)
*
|
2002-01-17 |
2007-02-08 |
Zhi Hong |
Sugar modified nucleosides as viral replication inhibitors
|
US7323453B2
(en)
|
2002-02-13 |
2008-01-29 |
Merck & Co., Inc. |
Methods of inhibiting orthopoxvirus replication with nucleoside compounds
|
US20030215917A1
(en)
*
|
2002-04-04 |
2003-11-20 |
Mingjun Huang |
Assay for evaluation of activity of compounds against HCV using a novel detection system in the HCV replicon
|
MXPA04009986A
(es)
*
|
2002-04-12 |
2005-08-16 |
Achillion Pharmaceuticals Inc |
Metodo para sintetizar beta-l-5-fluoro-2¦,3¦-didesoxi-2¦,3¦-dideshidrocitidina (¦-l-fd4c).
|
US20040121316A1
(en)
|
2002-04-26 |
2004-06-24 |
Gilead Sciences, Inc. |
Method and compositions for identifying anti-HIV therapeutic compounds
|
US7247621B2
(en)
|
2002-04-30 |
2007-07-24 |
Valeant Research & Development |
Antiviral phosphonate compounds and methods therefor
|
EP1501850A2
(fr)
*
|
2002-05-06 |
2005-02-02 |
Genelabs Technologies, Inc. |
Derives nucleosidiques destines au traitement de l'infection par le virus de l'hepatite c
|
US6982253B2
(en)
|
2002-06-05 |
2006-01-03 |
Supergen, Inc. |
Liquid formulation of decitabine and use of the same
|
JP2005530843A
(ja)
*
|
2002-06-21 |
2005-10-13 |
メルク エンド カムパニー インコーポレーテッド |
Rna依存性rnaウィルスポリメラーゼ阻害剤としてのヌクレオシド誘導体
|
WO2004003138A2
(fr)
*
|
2002-06-27 |
2004-01-08 |
Merck & Co., Inc. |
Derives nucleosidiques utilises comme inhibiteurs de l'arn polymerase arn-dependante virale
|
CN101172993A
(zh)
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
CN104193791A
(zh)
|
2002-06-28 |
2014-12-10 |
埃迪尼克斯医药公司 |
用于治疗黄病毒感染的修饰的2’和3’-核苷前药
|
BR0312278A
(pt)
*
|
2002-06-28 |
2007-06-19 |
Idenix Cayman Ltd |
éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
|
GB0215293D0
(en)
|
2002-07-03 |
2002-08-14 |
Rega Foundation |
Viral inhibitors
|
JP2005533108A
(ja)
*
|
2002-07-16 |
2005-11-04 |
メルク エンド カムパニー インコーポレーテッド |
Rna依存性rnaウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体
|
AU2003256619A1
(en)
|
2002-07-24 |
2004-02-09 |
Isis Pharmaceuticals, Inc. |
Pyrrolopyrimidine thionucleoside analogs as antivirals
|
US20050026853A1
(en)
*
|
2002-07-25 |
2005-02-03 |
Micrologix Biotech Inc. |
Anti-viral 7-deaza D-nucleosides and uses thereof
|
US20050058982A1
(en)
|
2002-07-26 |
2005-03-17 |
Chiron Corporation |
Modified small interfering RNA molecules and methods of use
|
MXPA05001298A
(es)
|
2002-08-01 |
2005-11-04 |
Pharmasset Inc |
Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae.
|
US20040067877A1
(en)
*
|
2002-08-01 |
2004-04-08 |
Schinazi Raymond F. |
2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
|
DE10238722A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
|
US7094768B2
(en)
|
2002-09-30 |
2006-08-22 |
Genelabs Technologies, Inc. |
Nucleoside derivatives for treating hepatitis C virus infection
|
AU2003279797B2
(en)
|
2002-09-30 |
2009-10-22 |
Genelabs Technologies, Inc. |
Nucleoside derivatives for treating hepatitis C virus infection
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
KR101115210B1
(ko)
*
|
2002-10-31 |
2012-04-12 |
메타베이시스 테라퓨틱스, 인크. |
신규 시타라빈 모노포스페이트 전구약물
|
SI1576138T1
(sl)
|
2002-11-15 |
2017-07-31 |
Idenix Pharmaceuticals Llc |
2'-metil nukleozidi v kombinaciji z interferon in flaviviridae mutacijo
|
US7034167B2
(en)
|
2002-12-06 |
2006-04-25 |
Merck & Co., Inc. |
Process to ribofuranose sugar derivatives as intermediates to branched-chain nucleosides
|
US7598373B2
(en)
|
2002-12-12 |
2009-10-06 |
Idenix Pharmaceuticals, Inc. |
Process for the production of 2-C-methyl-D-ribonolactone
|
JP2006514038A
(ja)
*
|
2002-12-23 |
2006-04-27 |
イデニクス(ケイマン)リミテツド |
3’−ヌクレオシドプロドラッグの生産方法
|
WO2004060346A2
(fr)
|
2002-12-30 |
2004-07-22 |
Angiotech International Ag |
Liberation de medicaments a partir d'une composition polymere a gelification rapide
|
US7223785B2
(en)
|
2003-01-22 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
AR043006A1
(es)
*
|
2003-02-12 |
2005-07-13 |
Merck & Co Inc |
Proceso para preparar ribonucleosidos ramificados
|
CA2529311A1
(fr)
*
|
2003-03-28 |
2004-10-07 |
Pharmasset, Inc. |
Composes permettant de traiter les infections par flavivirus
|
GB0307891D0
(en)
*
|
2003-04-04 |
2003-05-14 |
Angeletti P Ist Richerche Bio |
Chemical compounds,compositions and uses
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
EA200501676A1
(ru)
|
2003-04-25 |
2006-04-28 |
Джилид Сайэнс, Инк. |
Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
|
SG182849A1
(en)
|
2003-04-25 |
2012-08-30 |
Gilead Sciences Inc |
Antiviral phosphonate analogs
|
US7432261B2
(en)
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
WO2005002626A2
(fr)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Composes de phosphonate therapeutiques
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
WO2004096287A2
(fr)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Composes de phosphonate inhibiteurs de l'inosine monophosphate deshydrogenase
|
WO2004096285A2
(fr)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Analogues anti-infectieux du phosphonate
|
US20040259934A1
(en)
*
|
2003-05-01 |
2004-12-23 |
Olsen David B. |
Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
|
US7429572B2
(en)
|
2003-05-30 |
2008-09-30 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
CA2528044A1
(fr)
|
2003-06-04 |
2004-12-16 |
Genelabs Technologies, Inc. |
Derives heteroaryles contenant de l'azote
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
EP2157095A3
(fr)
*
|
2003-06-30 |
2010-09-08 |
Novartis AG |
Synthèse de bêta-L-2-désoxynucléosides
|
US7572581B2
(en)
|
2003-06-30 |
2009-08-11 |
Roche Molecular Systems, Inc. |
2′-terminator nucleotide-related methods and systems
|
US7947817B2
(en)
|
2003-06-30 |
2011-05-24 |
Roche Molecular Systems, Inc. |
Synthesis and compositions of 2'-terminator nucleotides
|
KR20060084845A
(ko)
|
2003-07-25 |
2006-07-25 |
이데닉스 (케이만) 리미티드 |
C형 간염을 포함하는 플라비비리다에를 치료하기 위한퓨린 뉴클레오시드 유사체
|
ZA200600424B
(en)
|
2003-08-01 |
2007-05-30 |
Genelabs Tech Inc |
Bicyclic imidazol derivatives against flaviviridae
|
WO2005018330A1
(fr)
*
|
2003-08-18 |
2005-03-03 |
Pharmasset, Inc. |
Regime de dosage pour therapie contre flaviviridae
|
MXPA06002198A
(es)
|
2003-08-27 |
2007-08-14 |
Biota Scient Management |
Nucleosidos o nucleotidos triciclicos novedosos como agentes terapeuticos.
|
TW201127828A
(en)
|
2003-09-05 |
2011-08-16 |
Vertex Pharma |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
RS20110578A3
(en)
|
2003-10-14 |
2016-02-29 |
F. Hoffmann-La Roche Ltd |
MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
|
US7151089B2
(en)
|
2003-10-27 |
2006-12-19 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
JP2007508843A
(ja)
|
2003-10-24 |
2007-04-12 |
ギリアード サイエンシーズ, インコーポレイテッド |
治療用化合物の同定のための方法および組成物
|
US7427624B2
(en)
|
2003-10-24 |
2008-09-23 |
Gilead Sciences, Inc. |
Purine nucleoside phosphorylase inhibitory phosphonate compounds
|
WO2005044308A1
(fr)
|
2003-10-24 |
2005-05-19 |
Gilead Sciences, Inc. |
Analogues phosphonates d'antimetabolites
|
US7202223B2
(en)
*
|
2003-10-27 |
2007-04-10 |
Genelabs Technologies, Inc. |
Nucleoside compounds for treating viral infections
|
CA2543116A1
(fr)
|
2003-10-27 |
2005-05-19 |
Genelabs Technologies, Inc. |
Procedes de preparation de derives 7-(2'-.szlig.-d-ribofuranosyl substitue)-4-(nr2r3)-5-(ethyn-1-yl substitue)-pyrrolo[2,3-d]pyrimidine
|
KR20060096487A
(ko)
*
|
2003-10-27 |
2006-09-11 |
진랩스 테크놀러지스, 인크. |
바이러스 감염증들을 치료하기 위한 뉴클레오시드 화합물
|
EP1687321A1
(fr)
*
|
2003-10-27 |
2006-08-09 |
Genelabs Technologies, Inc. |
Composes nucleosidiques de traitement d'infections virales
|
JP2007515495A
(ja)
|
2003-12-22 |
2007-06-14 |
ギリアード サイエンシーズ, インコーポレイテッド |
4’−置換カルボビル誘導体およびアバカビル誘導体ならびにhivおよびhcv抗ウイルス活性を有する関連化合物
|
US20070258946A1
(en)
*
|
2003-12-23 |
2007-11-08 |
Blatt Lawrence M |
Combination Therapy for Treating Hepatitis C Virus Infection
|
WO2005062949A2
(fr)
*
|
2003-12-23 |
2005-07-14 |
Intermune, Inc. |
Methode permettant de traiter l'infection par un hepatovirus
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
WO2005070955A1
(fr)
|
2004-01-21 |
2005-08-04 |
Boehringer Ingelheim International Gmbh |
Peptides macrocycliques actifs contre le virus de l'hepatite c
|
US20050182252A1
(en)
|
2004-02-13 |
2005-08-18 |
Reddy K. R. |
Novel 2'-C-methyl nucleoside derivatives
|
NZ549079A
(en)
|
2004-02-20 |
2010-08-27 |
Boehringer Ingelheim Int |
Viral polymerase inhibitors
|
US7754718B2
(en)
|
2004-05-05 |
2010-07-13 |
Yale University |
Antiviral helioxanthin analogs
|
AU2005254057B2
(en)
|
2004-06-15 |
2011-02-17 |
Isis Pharmaceuticals, Inc. |
C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
|
EP1912643A2
(fr)
*
|
2004-06-23 |
2008-04-23 |
Idenix (Cayman) Limited |
Derives de5-aza-7-deazapurine pour le traitement des infections a flaviviridae
|
EP1773355B1
(fr)
*
|
2004-06-24 |
2014-06-25 |
Merck Sharp & Dohme Corp. |
Phosphoramidates d'aryle nucleosidiques pour le traitement d'infection virale arn dependante de l'arn
|
US7745125B2
(en)
|
2004-06-28 |
2010-06-29 |
Roche Molecular Systems, Inc. |
2′-terminator related pyrophosphorolysis activated polymerization
|
JP4283738B2
(ja)
*
|
2004-07-08 |
2009-06-24 |
浜松ホトニクス株式会社 |
半導体レーザ装置
|
JP5078612B2
(ja)
*
|
2004-07-21 |
2012-11-21 |
ギリアド ファーマセット エルエルシー |
アルキル置換された2−デオキシ−2−フルオロ−d−リボフラノシルピリミジン類及びプリン類及びそれらの誘導体の調製
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
PT2258376T
(pt)
|
2004-07-27 |
2019-05-31 |
Gilead Sciences Inc |
Análogos fosfonatados de compostos inibidores do vih
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
JP2006077004A
(ja)
*
|
2004-08-11 |
2006-03-23 |
Chugai Pharmaceut Co Ltd |
抗hcv作用を有する化合物およびそれを含む医薬組成物
|
CN101044151B
(zh)
*
|
2004-08-23 |
2011-01-19 |
弗·哈夫曼-拉罗切有限公司 |
抗病毒的4'-叠氮基-核苷
|
SI3109244T1
(sl)
*
|
2004-09-14 |
2019-06-28 |
Gilead Pharmasset Llc |
Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov
|
KR20070061570A
(ko)
|
2004-10-01 |
2007-06-13 |
버텍스 파마슈티칼스 인코포레이티드 |
Hcv ns3-ns4a 프로테아제 저해
|
WO2006065335A2
(fr)
*
|
2004-10-21 |
2006-06-22 |
Merck & Co., Inc. |
Nucleosides de pyrrolo[2,3-d]pyrimidine fluores destines au traitement d'infections ribovirales dependantes de l'arn
|
MY141025A
(en)
|
2004-10-29 |
2010-02-25 |
Vertex Pharma |
Dose forms
|
NZ555441A
(en)
|
2004-10-29 |
2010-12-24 |
Biocryst Pharm Inc |
Therapeutic furopyrimidines and thienopyrimidines
|
WO2006068760A2
(fr)
|
2004-11-19 |
2006-06-29 |
The Regents Of The University Of California |
Pyrazolopyrimidines anti-inflammatoires
|
US7414031B2
(en)
|
2004-11-22 |
2008-08-19 |
Genelabs Technologies, Inc. |
5-nitro-nucleoside compounds for treating viral infections
|
WO2006093986A1
(fr)
*
|
2005-02-28 |
2006-09-08 |
Genelabs Technologies, Inc. |
Promedicaments nucleosidiques tricycliques destines au traitement d'infections virales
|
US7524831B2
(en)
|
2005-03-02 |
2009-04-28 |
Schering Corporation |
Treatments for Flaviviridae virus infection
|
AU2006222563A1
(en)
|
2005-03-08 |
2006-09-14 |
Biota Scientific Management Pty Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
EP1898934A1
(fr)
*
|
2005-03-09 |
2008-03-19 |
Idenix (Cayman) Limited |
Nucleosides a bases non naturelles en tant qu'agents anti-viraux
|
JP4516863B2
(ja)
*
|
2005-03-11 |
2010-08-04 |
株式会社ケンウッド |
音声合成装置、音声合成方法及びプログラム
|
US7250416B2
(en)
*
|
2005-03-11 |
2007-07-31 |
Supergen, Inc. |
Azacytosine analogs and derivatives
|
US8114847B2
(en)
|
2005-03-16 |
2012-02-14 |
Case Western Reserve University |
Selective inhibitors of translesion DNA replication
|
US9029345B2
(en)
*
|
2005-03-16 |
2015-05-12 |
Case Western Reserve University |
Selective inhibitors of translesion DNA replication
|
WO2006102594A1
(fr)
*
|
2005-03-23 |
2006-09-28 |
Genelabs Technologies, Inc. |
Promedicament nucleoside pour le traitement des infections virales
|
WO2007084157A2
(fr)
*
|
2005-03-23 |
2007-07-26 |
Genelabs Technologies, Inc. |
Promédicaments nucléosidiques pour le traitement d'infections virales
|
US7514410B2
(en)
*
|
2005-03-29 |
2009-04-07 |
Biocryst Pharmaceuticals, Inc. |
Hepatitis C therapies
|
WO2006130217A2
(fr)
*
|
2005-04-01 |
2006-12-07 |
The Regents Of The University Of California |
Esters de phosphate de phosphonates de nucleosides substitues
|
AR056327A1
(es)
*
|
2005-04-25 |
2007-10-03 |
Genelabs Tech Inc |
Compuestos de nucleosidos para el tratamiento de infecciones virales
|
WO2006119061A2
(fr)
*
|
2005-05-02 |
2006-11-09 |
Merck & Co., Inc. |
Inhibiteurs de la protease ns3 du vhc
|
WO2006122207A1
(fr)
*
|
2005-05-10 |
2006-11-16 |
Valeant Research & Development |
6-hydrazinopurine 2'-methyl ribonucleosides et nucleotides pour le traitement de hcv
|
US7569600B2
(en)
|
2005-05-13 |
2009-08-04 |
Virochem Pharma Inc. |
Compounds and methods for the treatment of prevention of Flavivirus infections
|
CN100478349C
(zh)
*
|
2005-06-20 |
2009-04-15 |
河南省凯特化学实业总公司 |
氟化核苷类化合物、其制备方法及其应用
|
US7470664B2
(en)
*
|
2005-07-20 |
2008-12-30 |
Merck & Co., Inc. |
HCV NS3 protease inhibitors
|
NZ565269A
(en)
|
2005-08-01 |
2010-03-26 |
Merck & Co Inc |
Macrocyclic peptides as HCV NS3 protease inhibitors
|
AU2006275413B2
(en)
*
|
2005-08-02 |
2012-07-19 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
UA91255C2
(uk)
|
2005-12-09 |
2010-07-12 |
Ф. Хоффманн-Ля Рош Аг |
Антивірусні нуклеозиди
|
EP1976382B1
(fr)
|
2005-12-23 |
2013-04-24 |
IDENIX Pharmaceuticals, Inc. |
Procede pour la preparation d'un intermediaire synthetique pour la preparation de nucleosides ramifies
|
AR059429A1
(es)
*
|
2006-02-09 |
2008-04-09 |
Schering Corp |
Combinaciones que involucran el (los) inhibidor(es) de la protesa hcv y metodos de tratamiento relacionados al (los) mismo (s)
|
WO2007098270A2
(fr)
|
2006-02-27 |
2007-08-30 |
Vertex Pharmaceuticals Incorporated |
Co-cristaux et compositions pharmaceutiques les comprenant
|
BRPI0709567A2
(pt)
|
2006-03-16 |
2011-07-12 |
Vertex Pharma |
inibidores deuterados de protease de hepatite c
|
CN101460488A
(zh)
*
|
2006-04-04 |
2009-06-17 |
弗·哈夫曼-拉罗切有限公司 |
用于hcv治疗的3’,5’-二-o-酰化核苷
|
NZ571182A
(en)
|
2006-04-04 |
2010-09-30 |
Univ California |
Pyrazolo[3,4-d]pyrimidines
|
NZ571826A
(en)
|
2006-04-11 |
2012-01-12 |
Novartis Ag |
HCV/HIV inhibitors and their uses
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
US7842672B2
(en)
|
2006-07-07 |
2010-11-30 |
Gilead Sciences, Inc. |
Phosphonate inhibitors of HCV
|
WO2008073165A2
(fr)
*
|
2006-08-25 |
2008-06-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Procédés et compositions permettant d'identifier des agents anti-hcv
|
SI2084175T1
(sl)
|
2006-10-10 |
2011-05-31 |
Medivir Ab |
Hcv nukleozidni inhibitor
|
BRPI0719174A2
(pt)
|
2006-10-10 |
2017-06-13 |
Hoffmann La Roche |
preparação de pirimidinas ribofuranosil nucleosídeos
|
JP5345941B2
(ja)
*
|
2006-10-24 |
2013-11-20 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Hcvns3プロテアーゼ阻害剤
|
US8377873B2
(en)
|
2006-10-24 |
2013-02-19 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
JP5345541B2
(ja)
|
2006-10-24 |
2013-11-20 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Hcvns3プロテアーゼ阻害剤
|
US8377874B2
(en)
|
2006-10-27 |
2013-02-19 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
WO2008057209A1
(fr)
*
|
2006-10-27 |
2008-05-15 |
Merck & Co., Inc. |
Inhibiteurs de protéase ns3 du vhc
|
EP2091927B1
(fr)
|
2006-11-09 |
2011-07-20 |
F. Hoffmann-La Roche AG |
Arylamides substituées thiazole et oxazole
|
BRPI0718915A2
(pt)
|
2006-11-15 |
2013-12-03 |
Virochem Pharma Inc |
Análogos de tiofeno para o tratamento ou prevenção de infecções por flavivírus
|
GB0623493D0
(en)
|
2006-11-24 |
2007-01-03 |
Univ Cardiff |
Chemical compounds
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CA2672250C
(fr)
|
2006-12-20 |
2013-04-30 |
Ian Stansfield |
Indoles antiviraux
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
JP2010515680A
(ja)
|
2007-01-05 |
2010-05-13 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Rna依存性rnaウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート
|
TW200838550A
(en)
*
|
2007-02-09 |
2008-10-01 |
Novartis Ag |
Organic compounds
|
TW200846343A
(en)
|
2007-02-27 |
2008-12-01 |
Vertex Pharma |
Co-crystals and pharmaceutical compositions comprising the same
|
CA2679426A1
(fr)
|
2007-02-27 |
2008-09-04 |
Luc Farmer |
Inhibiteurs de serine proteases
|
WO2008106167A1
(fr)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Polythérapie incluant des inhibiteurs de métalloprotéinases matricielles et des inhibiteurs de caspases pour le traitement de maladies hépatiques
|
AU2008219622A1
(en)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
|
PL2308514T3
(pl)
|
2007-03-23 |
2013-11-29 |
To Bbb Holding B V |
Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
AU2008251555B2
(en)
*
|
2007-05-10 |
2012-08-30 |
Biocryst Pharmaceuticals, Inc. |
Tetrahydrofuro [3 4-D] dioxolane compounds for use in the treatment of viral infections and cancer
|
GB0709791D0
(en)
*
|
2007-05-22 |
2007-06-27 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
US8871435B2
(en)
*
|
2007-06-27 |
2014-10-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for identifying agents that inhibit an NS4B-mediated neoplastic cellular phenotype of HCV infected cells
|
CN100532388C
(zh)
|
2007-07-16 |
2009-08-26 |
郑州大学 |
2’-氟-4’-取代-核苷类似物、其制备方法及应用
|
JP2010533699A
(ja)
|
2007-07-17 |
2010-10-28 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
C型肝炎感染症の治療のための大環状インドール誘導体
|
AU2008277377B2
(en)
*
|
2007-07-19 |
2013-08-01 |
Msd Italia S.R.L. |
Macrocyclic compounds as antiviral agents
|
CL2008002549A1
(es)
|
2007-08-30 |
2010-09-03 |
Vertex Pharma |
Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv.
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
WO2009046448A1
(fr)
*
|
2007-10-04 |
2009-04-09 |
Intellikine, Inc. |
Entités chimiques et leurs utilisations thérapeutiques
|
US20090318380A1
(en)
|
2007-11-20 |
2009-12-24 |
Pharmasset, Inc. |
2',4'-substituted nucleosides as antiviral agents
|
JP5498392B2
(ja)
|
2007-11-30 |
2014-05-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
1,5−ジヒドロ−ピラゾロ[3,4−d]ピリミジン−4−オン誘導体及びcns障害の治療のためのpde9aモジュレーターとしてのそれらの使用
|
JP5318882B2
(ja)
|
2007-12-17 |
2013-10-16 |
エフ.ホフマン−ラ ロシュ アーゲー |
新規なイミダゾール置換アリールアミド
|
CN101903348B
(zh)
|
2007-12-17 |
2013-08-14 |
霍夫曼-拉罗奇有限公司 |
吡唑取代的芳基酰胺
|
KR101290385B1
(ko)
|
2007-12-17 |
2013-07-29 |
에프. 호프만-라 로슈 아게 |
테트라졸-치환된 아릴아미드 유도체 및 p2x3 및/또는 p2x2/3 퓨린성 수용체 길항제로서의 이들의 용도
|
BRPI0821266B8
(pt)
|
2007-12-17 |
2023-02-07 |
Hoffmann La Roche |
Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
MY191407A
(en)
|
2008-01-04 |
2022-06-27 |
Intellikine Llc |
Certain chemical entities, compositions and methods
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
US8227431B2
(en)
*
|
2008-03-17 |
2012-07-24 |
Hetero Drugs Limited |
Nucleoside derivatives
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
CA2722308C
(fr)
*
|
2008-04-15 |
2024-02-27 |
Rfs Pharma, Llc. |
Derives nucleosidiques destines au traitement d'infections par un virus de la famille des caliciviridae, y compris d'infections par le norovirus
|
AU2013216595B2
(en)
*
|
2008-04-23 |
2016-07-28 |
Gilead Sciences, Inc. |
1' -substituted carba-nucleoside analogs for antiviral treatment
|
NO2937350T3
(fr)
|
2008-04-23 |
2018-06-09 |
|
|
AU2009241445A1
(en)
|
2008-04-28 |
2009-11-05 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
CA2724523A1
(fr)
|
2008-06-06 |
2010-01-07 |
Scynexis, Inc. |
Nouveaux peptides macrocycliques
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
WO2009150156A1
(fr)
*
|
2008-06-13 |
2009-12-17 |
Riboxx Gmbh |
Procédé permettant la synthèse enzymatique de l'arn modifié chimiquement
|
CA2729168A1
(fr)
*
|
2008-07-02 |
2010-02-04 |
Idenix Pharmaceuticals, Inc. |
Composes et compositions pharmaceutiques pour le traitement d'infections virales
|
WO2010002877A2
(fr)
*
|
2008-07-03 |
2010-01-07 |
Biota Scientific Management |
Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques
|
US9096611B2
(en)
|
2008-07-08 |
2015-08-04 |
Intellikine Llc |
Kinase inhibitors and methods of use
|
US20110224223A1
(en)
*
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
CN102089318B
(zh)
|
2008-07-08 |
2014-05-21 |
吉里德科学公司 |
Hiv抑制剂化合物的盐
|
US7973040B2
(en)
|
2008-07-22 |
2011-07-05 |
Merck Sharp & Dohme Corp. |
Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
|
JP5146785B2
(ja)
*
|
2008-07-24 |
2013-02-20 |
国立大学法人九州大学 |
酵素基質修飾ヌクレオシド三リン酸誘導体
|
JP4621926B2
(ja)
*
|
2008-07-24 |
2011-02-02 |
国立大学法人九州大学 |
酵素基質修飾ヌクレオシド三リン酸、核酸プローブ、マルチラベル化核酸プローブ、マルチラベル化核酸プローブの製造方法および標的核酸の検出方法
|
WO2010015637A1
(fr)
*
|
2008-08-06 |
2010-02-11 |
Novartis Ag |
Nouveaux nucléosides modifiés antiviraux
|
CN102203095A
(zh)
|
2008-08-11 |
2011-09-28 |
葛兰素史密丝克莱恩有限责任公司 |
用于治疗变应性疾病、炎性疾病和感染性疾病的嘌呤衍生物
|
EP2320905B1
(fr)
|
2008-08-11 |
2017-06-28 |
Glaxosmithkline LLC |
Nouveaux dérivés d'adénine
|
UA103195C2
(uk)
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
PE20110383A1
(es)
|
2008-09-08 |
2011-07-15 |
Boehringer Ingelheim Int |
Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
|
JP5731978B2
(ja)
|
2008-09-26 |
2015-06-10 |
インテリカイン, エルエルシー |
複素環キナーゼ阻害剤
|
EP3025727A1
(fr)
|
2008-10-02 |
2016-06-01 |
The J. David Gladstone Institutes |
Procédés de traitement des maladies du foie
|
DK2358720T3
(en)
|
2008-10-16 |
2016-06-06 |
Univ California |
Heteroarylkinaseinhibitorer fused-ring
|
US8476431B2
(en)
*
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
BRPI0923225A2
(pt)
|
2008-12-02 |
2016-10-04 |
Chiralgen Ltd |
metodo para sintese de acidos nucleicos modificados no atomo de fosforo
|
PA8855701A1
(es)
|
2008-12-23 |
2010-07-27 |
|
Análogos de nucleósidos
|
EA019341B1
(ru)
|
2008-12-23 |
2014-02-28 |
Джилид Фармассет, Ллс. |
Фосфорамидаты нуклеозидов
|
WO2010075554A1
(fr)
*
|
2008-12-23 |
2010-07-01 |
Pharmasset, Inc. |
Synthèse de nucléosides de type purine
|
WO2010082050A1
(fr)
|
2009-01-16 |
2010-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Composés benzoxazocines substitués 7-aminoalkyle macrocycycliques destinés au traitement des infections par hépatite c
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
MX2011007771A
(es)
*
|
2009-01-21 |
2011-08-12 |
Hoffmann La Roche |
Composiciones farmaceuticas que comprenden un profarmaco inhibidor de la polimerasa del virus de la hepatitis c (hcv).
|
AU2010213873B2
(en)
|
2009-02-10 |
2015-07-09 |
Gilead Sciences, Inc. |
Carba-nucleoside analogs for antiviral treatment
|
EP2396028A2
(fr)
|
2009-02-12 |
2011-12-21 |
Vertex Pharmceuticals Incorporated |
Polythérapie contre le hcv comprenant de l'interféron pégylé, de la ribavirine et de la telaprevir
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス,インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤
|
JP2012520884A
(ja)
|
2009-03-18 |
2012-09-10 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー |
フラビウイルス科ウイルス感染症を治療する方法および組成物
|
EP2408306A4
(fr)
*
|
2009-03-20 |
2012-11-07 |
Alios Biopharma Inc |
Nucleoside substitue et analogues nucleotidiques
|
EA201101395A1
(ru)
|
2009-03-31 |
2012-06-29 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Производные 1-гетероциклил-1,5-дигидропиразоло[3,4d]пиримидин-4-oha и их применение в качестве модуляторов pde9a
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
CN104497084B
(zh)
*
|
2009-04-22 |
2018-06-05 |
捷克有机化学和生物化学研究院 |
用于治疗用途的7-脱氮嘌呤核苷
|
WO2010129816A2
(fr)
|
2009-05-07 |
2010-11-11 |
Intellikine, Inc. |
Composés hétérocycliques et leurs utilisations
|
JO3027B1
(ar)
*
|
2009-05-14 |
2016-09-05 |
Janssen Products Lp |
نيوكليوسيدات يوراسيل سبيرواوكسيتان
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
TW201107342A
(en)
*
|
2009-05-20 |
2011-03-01 |
Chimerix Inc |
Compounds, compositions and methods for treating viral infection
|
SG176640A1
(en)
|
2009-06-22 |
2012-01-30 |
Hoffmann La Roche |
Novel oxazolone and pyrrolidinone-substituted arylamides
|
JP5540087B2
(ja)
|
2009-06-22 |
2014-07-02 |
エフ.ホフマン−ラ ロシュ アーゲー |
P2x3および/またはp2x2/3アンタゴニストとしての、新規なインドール、インダゾールおよびベンゾイミダゾールアリールアミド
|
EP2445868B1
(fr)
|
2009-06-22 |
2013-12-18 |
F.Hoffmann-La Roche Ag |
Amides biphényles utiles en tant que modulateurs des récepteurs p2x3 et/ou p2x2/3
|
BR112012000828A8
(pt)
|
2009-07-06 |
2017-10-10 |
Ontorii Inc |
Novas pró-drogas de ácido nucleico e métodos de uso das mesmas
|
US8828930B2
(en)
|
2009-07-30 |
2014-09-09 |
Merck Sharp & Dohme Corp. |
Hepatitis C virus NS3 protease inhibitors
|
CA2769652A1
(fr)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Inhibiteurs macrocycliques de la serine protease macrocyclique utiles contre les infections virales, en particulier le virus de l?hepatite c
|
AR077859A1
(es)
|
2009-08-12 |
2011-09-28 |
Boehringer Ingelheim Int |
Compuestos para el tratamiento de trastornos del snc
|
US8796394B2
(en)
*
|
2009-08-27 |
2014-08-05 |
Northwestern University |
Antifouling hydrogels, coatings, and methods of synthesis and use thereof
|
US10023600B2
(en)
|
2009-09-21 |
2018-07-17 |
Gilead Sciences, Inc. |
Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
|
US7973013B2
(en)
|
2009-09-21 |
2011-07-05 |
Gilead Sciences, Inc. |
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
|
HUE032252T2
(en)
*
|
2009-09-21 |
2017-09-28 |
Gilead Sciences Inc |
2'-fluoro-substituted carba-nucleoside analogs for antiviral treatment
|
US8455451B2
(en)
|
2009-09-21 |
2013-06-04 |
Gilead Sciences, Inc. |
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
|
WO2011047384A2
(fr)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Procédés d'inhibition de l'activité ire1
|
KR101774035B1
(ko)
|
2009-10-30 |
2017-09-01 |
얀센 파마슈티카 엔.브이. |
이미다조[1,2―b]피리다진 유도체 및 PDE10 저해제로서의 그의 용도
|
AU2010317996A1
(en)
|
2009-11-14 |
2012-05-10 |
F. Hoffmann-La Roche Ag |
Biomarkers for predicting rapid response to HCV treatment
|
KR101840479B1
(ko)
*
|
2009-11-16 |
2018-03-20 |
유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 |
바이러스 감염 치료를 위한 2'―플루오로―6'―메틸렌 카보사이클릭 뉴클레오사이드 및 방법
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
JP2013512247A
(ja)
|
2009-11-25 |
2013-04-11 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染症の治療または予防のための5−アルキニル−チオフェン−2−カルボン酸誘導体およびそれらの使用
|
BR112012011393A2
(pt)
|
2009-12-02 |
2017-06-20 |
Hoffmann La Roche |
biomarcadores para a previsão da resposta sustentada ao tratamento de hcv
|
KR20120118008A
(ko)
|
2009-12-18 |
2012-10-25 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
5,5-융합 아릴렌 또는 헤테로아릴렌 간염 c 바이러스 억제제
|
WO2011079327A1
(fr)
|
2009-12-24 |
2011-06-30 |
Vertex Pharmaceuticals Incorporated |
Analogues destinés au traitement ou à la prévention d'infections à flavivirus
|
JP5704481B2
(ja)
*
|
2010-01-22 |
2015-04-22 |
国立大学法人九州大学 |
核酸検出用キット
|
EP2528930B1
(fr)
*
|
2010-01-28 |
2013-10-30 |
F.Hoffmann-La Roche Ag |
4'-azido-nucléosides utilisés en tant que composés anti-vhc
|
JP2013518124A
(ja)
|
2010-01-29 |
2013-05-20 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
C型肝炎ウイルス感染の処置のための治療法
|
US8703754B2
(en)
|
2010-02-10 |
2014-04-22 |
Glaxosmithkline Llc |
6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8H-purin-8-one maleate
|
WO2011098451A1
(fr)
|
2010-02-10 |
2011-08-18 |
Glaxosmithkline Llc |
Dérivés de purine et leurs utilisations pharmaceutiques
|
AR080754A1
(es)
|
2010-03-09 |
2012-05-09 |
Janssen Pharmaceutica Nv |
Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
|
TW201139438A
(en)
|
2010-03-24 |
2011-11-16 |
Vertex Pharma |
Analogues for the treatment or prevention of flavivirus infections
|
CA2794145A1
(fr)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues pour traiter ou prevenir les infections a flavivirus
|
WO2011119860A1
(fr)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues pour traiter ou prévenir les infections à flavivirus
|
TW201200522A
(en)
|
2010-03-24 |
2012-01-01 |
Vertex Pharma |
Analogues for the treatment or prevention of flavivirus infections
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
BR112012024884A2
(pt)
|
2010-03-31 |
2016-10-18 |
Gilead Pharmasset Llc |
síntese estereosseletiva de ativos contendo fósforo
|
EP2552933A1
(fr)
|
2010-03-31 |
2013-02-06 |
Gilead Pharmasset LLC |
Phosphoramidate de nucléoside de type purine
|
CA2795054A1
(fr)
|
2010-04-01 |
2011-10-06 |
Idenix Pharmaceuticals, Inc. |
Composes et compositions pharmaceutiques pour le traitement d'infections virales
|
EP2571357B1
(fr)
|
2010-05-21 |
2016-07-06 |
Infinity Pharmaceuticals, Inc. |
Composés chimiques, compositions et procédés pour modulation de kinases
|
TW201201815A
(en)
|
2010-05-28 |
2012-01-16 |
Gilead Sciences Inc |
1'-substituted-carba-nucleoside prodrugs for antiviral treatment
|
WO2011156545A1
(fr)
|
2010-06-09 |
2011-12-15 |
Vertex Pharmaceuticals Incorporated |
Modèle dynamique viral pour une polythérapie contre le vhc
|
WO2011159826A2
(fr)
|
2010-06-15 |
2011-12-22 |
Vertex Pharmaceuticals Incorporated |
Mutants de la protéase ns5b du vhc
|
WO2012006070A1
(fr)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Composés et méthodes de traitement ou de prévention d'infections à flavivirus
|
EP2585447A2
(fr)
|
2010-06-28 |
2013-05-01 |
Vertex Pharmaceuticals Incorporated |
Composés et méthodes pour le traitement ou la prévention d'infections par flavivirus
|
JP2013531011A
(ja)
|
2010-06-28 |
2013-08-01 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染の処置または予防のための化合物および方法
|
AR082215A1
(es)
|
2010-07-14 |
2012-11-21 |
Vertex Pharma |
Composicion farmaceutica agradable al paladar
|
CN103052646A
(zh)
|
2010-07-19 |
2013-04-17 |
吉里德科学公司 |
用于制备非对映异构体纯氨基磷酸酯前药的方法
|
AP3269A
(en)
|
2010-07-22 |
2015-05-31 |
Gilead Sciences Inc |
Methods and compounds for treating paramyxoviridaevirus infections
|
SG187081A1
(en)
|
2010-08-12 |
2013-03-28 |
Boehringer Ingelheim Int |
6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
CA2808291A1
(fr)
|
2010-08-17 |
2012-02-23 |
Vertex Pharmaceuticals Incorporated |
Composes et methodes de traitement ou de prevention d'infections virales par des flaviviridae
|
AU2011306066B2
(en)
*
|
2010-09-20 |
2015-01-29 |
Gilead Sciences, Inc. |
2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
|
EP2619215B1
(fr)
|
2010-09-22 |
2018-09-05 |
Alios Biopharma, Inc. |
Azido nucléosides et analogues nucléotidiques
|
SG188497A1
(en)
|
2010-09-22 |
2013-05-31 |
Alios Biopharma Inc |
Substituted nucleotide analogs
|
WO2012039448A1
(fr)
|
2010-09-24 |
2012-03-29 |
株式会社キラルジェン |
Groupe auxiliaire asymétrique
|
CN103179966B
(zh)
|
2010-10-08 |
2017-03-15 |
诺瓦提斯公司 |
磺酰胺ns3抑制剂的维生素e制剂
|
EP2637669A4
(fr)
|
2010-11-10 |
2014-04-02 |
Infinity Pharmaceuticals Inc |
Composés hétérocycliques et utilisations de ceux-ci
|
EP2646453A1
(fr)
|
2010-11-30 |
2013-10-09 |
Gilead Pharmasset LLC |
Composés
|
WO2012080050A1
(fr)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Formes solides d'un composé de phénoxybenzènesulfonyle
|
CA2819041A1
(fr)
|
2010-12-22 |
2012-06-28 |
Alios Biopharma, Inc. |
Analogues de nucleotides cycliques
|
DK2663309T3
(en)
|
2011-01-10 |
2017-06-19 |
Infinity Pharmaceuticals Inc |
METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
WO2012109646A1
(fr)
|
2011-02-11 |
2012-08-16 |
Vertex Pharmaceuticals Incorporated |
Traitement du vhc chez des patients infectés par le vih
|
US20130040971A1
(en)
|
2011-02-14 |
2013-02-14 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
US9295673B2
(en)
|
2011-02-23 |
2016-03-29 |
Intellikine Llc |
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
WO2012154321A1
(fr)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Composés et compositions pharmaceutiques pour le traitement d'infections virales
|
WO2012142075A1
(fr)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
Dérivés de nucléosides à substitution 2'-azido et leurs procédés d'utilisation pour le traitement de maladies virales
|
ES2744587T3
(es)
|
2011-04-13 |
2020-02-25 |
Gilead Sciences Inc |
Análogos de N-nucleósido de pirimidina 1-sustituidos para un tratamiento antiviral
|
WO2012142093A2
(fr)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
Dérivés nucléosides à substitution 2'-cyano et leurs procédés d'utilisation pour traitement de maladies virales
|
SG194485A1
(en)
|
2011-04-13 |
2013-12-30 |
Merck Sharp & Dohme |
2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
CN103619846B
(zh)
|
2011-06-27 |
2016-08-17 |
詹森药业有限公司 |
1-芳基-4-甲基-[1,2,4]三唑[4,3-a]喹喔啉衍生物
|
WO2013009735A1
(fr)
|
2011-07-13 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
Dérivés de nucléosides 5'-substitués et leurs procédés d'utilisation pour le traitement de maladies virales
|
WO2013009737A1
(fr)
|
2011-07-13 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
Analogues de nucléosides 5'-substitués et leurs procédés d'utilisation pour le traitement de maladies virales
|
EP2734520B1
(fr)
|
2011-07-19 |
2016-09-14 |
Infinity Pharmaceuticals, Inc. |
Composés hétérocycliques et leurs utilisations
|
EP3248982A1
(fr)
|
2011-07-19 |
2017-11-29 |
Wave Life Sciences Ltd. |
Reactifs de type thiosulfonate pour la synthèse d'acides nucléiques fonctionnalisés
|
CN103946226A
(zh)
|
2011-07-19 |
2014-07-23 |
无限药品股份有限公司 |
杂环化合物及其应用
|
WO2013016491A1
(fr)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Composés de thiophène
|
WO2013016499A1
(fr)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Procédés de préparation de composés du thiophène
|
SG11201400310WA
(en)
|
2011-08-29 |
2014-06-27 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
CN103945902B
(zh)
|
2011-08-30 |
2018-07-20 |
阿斯泰克斯制药公司 |
地西他滨衍生物制剂
|
WO2013033705A2
(fr)
|
2011-09-01 |
2013-03-07 |
Case Western Reserve University |
Nucléosides non endogènes en tant qu'agents théranostiques
|
CA2846496C
(fr)
|
2011-09-02 |
2020-07-14 |
The Regents Of The University Of California |
Pyrazolo[3,4-d]pyrimidines substituees et utilisations de celles-ci
|
US9403863B2
(en)
|
2011-09-12 |
2016-08-02 |
Idenix Pharmaceuticals Llc |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
US8951985B2
(en)
|
2011-09-12 |
2015-02-10 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
CN104244945B
(zh)
|
2011-09-16 |
2016-08-31 |
吉利德制药有限责任公司 |
用于治疗hcv的方法
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
MX2014004729A
(es)
|
2011-10-21 |
2014-07-28 |
Abbvie Inc |
Tratamiento en combinacion (por ejemplo, con abt-072 o abt-333) de agentes antivirales de accion directa para utilizarse en el tratamiento del virus de la hepatitis c.
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
SE1450019A1
(sv)
|
2011-10-21 |
2014-01-10 |
Abbvie Inc |
Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
EP2776438A4
(fr)
*
|
2011-11-10 |
2015-04-29 |
Inhibitex Inc |
Nucléosides de purine substitués, dérivés phosphoramidate et phosphordiamidate destinés à traiter des infections virales
|
US9328138B2
(en)
|
2011-11-15 |
2016-05-03 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
BR112014013224B1
(pt)
|
2011-11-30 |
2023-03-07 |
Emory University |
Inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais
|
WO2013084165A1
(fr)
*
|
2011-12-05 |
2013-06-13 |
Medivir Ab |
Inhibiteurs de vhc polymérase
|
US9364484B2
(en)
|
2011-12-06 |
2016-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for treating viral diseases
|
CA2860234A1
(fr)
|
2011-12-22 |
2013-06-27 |
Alios Biopharma, Inc. |
Analogues de nucleotide phosphorothioate substitue
|
MX356509B
(es)
|
2011-12-22 |
2018-05-30 |
Alios Biopharma Inc |
Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
|
WO2013106344A1
(fr)
|
2012-01-12 |
2013-07-18 |
Ligand Pharmaceuticals, Inc. |
Nucléosides 2'-c-méthyl comprenant un diester de phosphate cyclique de 1,3-propanediol (2-oxo-[1,3,2]-dioxaphosphorinane à la position 5'
|
WO2013116339A1
(fr)
|
2012-01-31 |
2013-08-08 |
Vertex Pharmaceuticals Incorporated |
Formulations très puissantes de vx-950
|
WO2013133927A1
(fr)
|
2012-02-13 |
2013-09-12 |
Idenix Pharmaceuticals, Inc. |
Compositions pharmaceutiques de 2'-c-méthyl-guanosine, 5'-[2-[(3-hydroxy-2,2-diméthyl-1-oxopropyl)thio]éthyl n-(phénylméthyl)phosphoramidate]
|
EA201491525A1
(ru)
|
2012-02-14 |
2014-12-30 |
Юниверсити Оф Джорджиа Рисерч Фаундэйшн, Инк. |
Спиро[2.4]гептаны для лечения инфекций, вызванных flaviviridae
|
ES2878087T3
(es)
*
|
2012-03-13 |
2021-11-18 |
Gilead Sciences Inc |
Análogos de carba-nucleósido 2-sustituidos para el tratamiento antiviral
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
SG10201804571TA
(en)
|
2012-03-21 |
2018-07-30 |
Alios Biopharma Inc |
Substituted nucleosides, nucleotides and analogs thereof
|
US8916538B2
(en)
|
2012-03-21 |
2014-12-23 |
Vertex Pharmaceuticals Incorporated |
Solid forms of a thiophosphoramidate nucleotide prodrug
|
WO2013142157A1
(fr)
|
2012-03-22 |
2013-09-26 |
Alios Biopharma, Inc. |
Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
PE20150132A1
(es)
|
2012-05-22 |
2015-02-14 |
Idenix Pharmaceuticals Inc |
Compuestos d-aminoacidos para enfermedad hepatica
|
EP2852605B1
(fr)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
Promédicaments de 3',5'-phosphate cyclique pour traiter une infection par le virus de l'hépatite c
|
EP2852604B1
(fr)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
|
US9422323B2
(en)
|
2012-05-25 |
2016-08-23 |
Janssen Sciences Ireland Uc |
Uracyl spirooxetane nucleosides
|
US9206412B2
(en)
*
|
2012-05-31 |
2015-12-08 |
Colorado State University Research Foundation |
Thioxothiazolidine inhibitors
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
CN104411312B
(zh)
|
2012-06-26 |
2018-03-06 |
詹森药业有限公司 |
包括pde2抑制剂例如1‑芳基‑4‑甲基‑[1,2,4]三唑[4,3‑a]‑喹喔啉化合物和pde10抑制剂的用于在治疗神经病学障碍或代谢障碍中使用的组合
|
ES2607184T3
(es)
|
2012-07-09 |
2017-03-29 |
Janssen Pharmaceutica, N.V. |
Inhibidores de la enzima fosfodiesterasa 10
|
PT2872485T
(pt)
|
2012-07-13 |
2021-03-05 |
Wave Life Sciences Ltd |
Grupo auxiliar assimétrico
|
RU2015104762A
(ru)
|
2012-07-13 |
2018-08-31 |
Уэйв Лайф Сайенсес Лтд. |
Хиральный контроль
|
SG11201500243WA
(en)
|
2012-07-13 |
2015-04-29 |
Shin Nippon Biomedical Lab Ltd |
Chiral nucleic acid adjuvant
|
EP2890704B1
(fr)
|
2012-08-31 |
2018-02-28 |
Novartis AG |
Dérivés de 2'-éthynyle nucléoside de traitement d'infections virales
|
MX2015003874A
(es)
|
2012-09-26 |
2015-12-16 |
Univ California |
Modulacion de ire1.
|
US9192621B2
(en)
|
2012-09-27 |
2015-11-24 |
Idenix Pharmaceuticals Llc |
Esters and malonates of SATE prodrugs
|
AP2015008384A0
(en)
|
2012-10-08 |
2015-04-30 |
Univ Montpellier Ct Nat De La Rech Scient |
2'-Chloro nucleoside analogs for hcv infection
|
US9242988B2
(en)
|
2012-10-17 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
AR092959A1
(es)
|
2012-10-17 |
2015-05-06 |
Merck Sharp & Dohme |
Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
|
WO2014059902A1
(fr)
|
2012-10-17 |
2014-04-24 |
Merck Sharp & Dohme Corp. |
Dérivés nucléosides substitués 2'-disubstitués et leurs procédés d'utilisation pour le traitement de maladies virales
|
WO2014063019A1
(fr)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Composés dinucléotides contre une infection par le vhc
|
WO2014066239A1
(fr)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
Nucléosides 2', 4'-pontés pour l'infection par le vhc
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
US20140140952A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Sp-Nucleoside Analog
|
MX2015006248A
(es)
|
2012-11-19 |
2015-08-14 |
Merck Sharp & Dohme |
Derivados de nucleosido 2'-alquinilo sustituido para el tratamiento de enfermedades virales.
|
EP2935304A1
(fr)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro-nucléosides pour le traitement du vhc
|
WO2014100498A1
(fr)
|
2012-12-21 |
2014-06-26 |
Alios Biopharma, Inc. |
Nucléosides, nucléotides substitués et leurs analogues
|
PT2935303T
(pt)
|
2012-12-21 |
2021-04-30 |
Alios Biopharma Inc |
4'-fluoro-nucleósidos, 4'-fluoro-nucleótidos e seus análogos para o tratamento de hcv
|
SG11201506021XA
(en)
|
2013-01-31 |
2015-08-28 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
WO2014121418A1
(fr)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques tétracycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c
|
WO2014121416A1
(fr)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
|
WO2014121417A1
(fr)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
|
US9821173B2
(en)
*
|
2013-02-08 |
2017-11-21 |
Case Western Reserve University |
Anti-cancer agents and methods of use
|
WO2014134251A1
(fr)
|
2013-02-28 |
2014-09-04 |
Vertex Pharmaceuticals Incorporated |
Compositions pharmaceutiques
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
EP2970358B1
(fr)
|
2013-03-04 |
2021-06-30 |
Idenix Pharmaceuticals LLC |
3'-désoxynucléosides utilisables en vue du traitement d'une infection par le vhc
|
US20140271547A1
(en)
|
2013-03-13 |
2014-09-18 |
Idenix Pharmaceuticals, Inc. |
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
RU2534613C2
(ru)
|
2013-03-22 |
2014-11-27 |
Александр Васильевич Иващенко |
Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
|
WO2014165542A1
(fr)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoronucléosides pour le traitement du vhc
|
CA2909270A1
(fr)
|
2013-04-12 |
2014-10-16 |
Achillion Pharmaceuticals, Inc. |
Derive de nucleoside d'activite elevee pour le traitement du vhc
|
WO2014197578A1
(fr)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc)
|
PE20160205A1
(es)
|
2013-06-26 |
2016-05-21 |
Alios Biopharma Inc |
Nucleosidos sustituidos, nucleotidos y analogos de los mismos
|
ES2952714T3
(es)
|
2013-06-26 |
2023-11-03 |
Janssen Pharmaceuticals Inc |
Nucleósidos sustituidos, nucleótidos y análogos de los mismos
|
WO2015017713A1
(fr)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
Pronucléotides phosphoramidates avec acides aminés d de composés halogéno pyrimidines pour le traitement des hépatopathies
|
PT3650014T
(pt)
|
2013-08-27 |
2021-12-27 |
Gilead Pharmasset Llc |
Formulação combinada de dois compostos antivirais
|
WO2015042375A1
(fr)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Inhibiteurs du virus de l'hépatite c
|
WO2015042447A1
(fr)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Nucléosides thérapeutiques ciblées et leur utilisation
|
BR112016007467B1
(pt)
|
2013-10-04 |
2022-09-20 |
Infinity Pharmaceuticals, Inc |
Compostos heterocíclicos e usos dos mesmos
|
WO2015051241A1
(fr)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Composés hétérocycliques et leurs utilisations
|
KR102314960B1
(ko)
*
|
2013-10-11 |
2021-10-19 |
얀센 바이오파마, 인코퍼레이트. |
치환된 뉴클레오사이드, 뉴클레오타이드 및 이의 유사체
|
WO2015061683A1
(fr)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc
|
EP3063165A1
(fr)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
Pronucléotides phosphoramidates de d-alanine de composés de nucléoside 2'-méthyl 2'-fluoro guanosine dans le traitement du vhc
|
CZ305466B6
(cs)
*
|
2013-11-04 |
2015-10-14 |
Ústav organické chemie a biochemie Akademie věd České republiky, v. v. i. |
Substituované 7-deazapurinové ribonukleosidy pro terapeutické použití
|
EP3074399A1
(fr)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
Analogues de nucléoside 2'-dichloro et 2'-fluoro-2'-chloro analogues pour l'infection par le vhc
|
WO2015095419A1
(fr)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
Nucléosides 4'-or pour le traitement du vhc
|
EP3095461A4
(fr)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité
|
US10322173B2
(en)
|
2014-01-15 |
2019-06-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
KR20230152178A
(ko)
|
2014-01-16 |
2023-11-02 |
웨이브 라이프 사이언시스 리미티드 |
키랄 디자인
|
CN106061984A
(zh)
|
2014-02-13 |
2016-10-26 |
配体药物公司 |
前药化合物及其用途
|
WO2015124591A1
(fr)
|
2014-02-20 |
2015-08-27 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Dérivés de pyrrolo[3,2]pyrimidine en tant qu'inducteurs d'interféron humain
|
WO2015134560A1
(fr)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Formes solides d'un composé inhibiteur des virus de la famille des flaviviridae et sels de celui-ci
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
JP6701088B2
(ja)
|
2014-03-19 |
2020-05-27 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
Pi3k−ガンマ媒介障害の治療で使用するための複素環式化合物
|
WO2015160975A2
(fr)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Polythérapies
|
WO2015161137A1
(fr)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c
|
CN106459133B
(zh)
*
|
2014-06-10 |
2019-12-06 |
安捷伦科技有限公司 |
用于“z核苷酸”的保护基团及其方法
|
TN2016000566A1
(en)
|
2014-06-24 |
2018-04-04 |
Alios Biopharma Inc |
Substituted nucleosides, nucleotides and analogs thereof
|
CN106573011A
(zh)
|
2014-06-24 |
2017-04-19 |
艾丽奥斯生物制药有限公司 |
取代的核苷、核苷酸和其类似物
|
EP3164136A4
(fr)
|
2014-07-02 |
2018-04-04 |
Ligand Pharmaceuticals, Inc. |
Composés de promédicaments et leurs utilisations
|
WO2016054491A1
(fr)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Composés hétérocycliques et leurs utilisations
|
TWI687432B
(zh)
|
2014-10-29 |
2020-03-11 |
美商基利科學股份有限公司 |
絲狀病毒科病毒感染之治療
|
BE1023340B1
(fr)
|
2014-11-13 |
2017-02-08 |
Glaxosmithkline Biologicals S.A. |
Composes
|
MA41441A
(fr)
|
2014-12-19 |
2017-12-12 |
Alios Biopharma Inc |
Nucléosides substitués, nucléotides et analogues de ceux-ci
|
MA41213A
(fr)
|
2014-12-19 |
2017-10-24 |
Alios Biopharma Inc |
Nucléosides substitués, nucléotides et analogues de ceux-ci
|
KR20220025914A
(ko)
|
2015-03-06 |
2022-03-03 |
아테아 파마슈티컬즈, 인크. |
HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
|
EP3303362B1
(fr)
|
2015-06-03 |
2022-10-19 |
Teva Pharmaceuticals International GmbH |
Procédés perfectionnés de préparation de sofosbuvir et d'intermédiaires de celui-ci
|
AU2016287585B2
(en)
|
2015-07-02 |
2020-12-17 |
Otsuka Pharmaceutical Co., Ltd. |
Lyophilized pharmaceutical compositions
|
JP2018523665A
(ja)
|
2015-08-06 |
2018-08-23 |
キメリックス インコーポレイテッド |
抗ウイルス剤として有用なピロロピリミジンヌクレオシドおよびその類縁体
|
WO2017027645A1
(fr)
|
2015-08-13 |
2017-02-16 |
Merck Sharp & Dohme Corp. |
Composés di-nucléotidiques cycliques en tant qu'agonistes de sting
|
CN108350016B
(zh)
|
2015-09-02 |
2021-07-27 |
艾伯维公司 |
抗病毒四氢呋喃衍生物
|
EP3350183A1
(fr)
|
2015-09-14 |
2018-07-25 |
Infinity Pharmaceuticals, Inc. |
Formes solides de dérivés d'isoquinolinone, leur procédé de fabrication, compositions les comprenant et méthodes d'utilisation de celles-ci
|
PT3349758T
(pt)
|
2015-09-16 |
2022-07-13 |
Gilead Sciences Inc |
Métodos para o tratamento de infeções pelo vírus arenaviridae
|
US10953029B2
(en)
*
|
2015-09-23 |
2021-03-23 |
Merck Sharp & Dohme Corp. |
4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof
|
CA3006930A1
(fr)
|
2015-12-03 |
2017-06-08 |
Glaxosmithkline Intellectual Property Development Limited |
Dinucleotides cycliques de purine a titre de modulateurs du sting
|
EP3426642A4
(fr)
|
2016-03-09 |
2019-10-09 |
Janssen BioPharma, Inc. |
Antiviraux acycliques
|
WO2017161116A1
(fr)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k
|
EP4292658A3
(fr)
|
2016-03-24 |
2024-03-06 |
Novartis AG |
Analogues d'alcynyl nucléoside en tant qu'inhibiteurs du rhinovirus humain
|
EA201892128A1
(ru)
|
2016-04-07 |
2019-04-30 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Гетероциклические амиды, полезные в качестве модуляторов
|
CN109608443B
(zh)
|
2016-04-07 |
2021-09-07 |
葛兰素史密斯克莱知识产权发展有限公司 |
用作蛋白质调节剂的杂环酰胺
|
CN109689063A
(zh)
|
2016-04-28 |
2019-04-26 |
埃默里大学 |
含有炔烃的核苷酸和核苷治疗组合物及其相关用途
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2017223422A1
(fr)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Polythérapies
|
US10202412B2
(en)
|
2016-07-08 |
2019-02-12 |
Atea Pharmaceuticals, Inc. |
β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
|
WO2018013937A1
(fr)
|
2016-07-14 |
2018-01-18 |
Atea Pharmaceuticals, Inc. |
Nucléotides de purine beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substitué-4'-fluoro-n6-substitué-6-amino-2-substitué pour le traitement de l'infection par le virus de l'hépatite c
|
US20190169221A1
(en)
*
|
2016-08-12 |
2019-06-06 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
CN116036114A
(zh)
|
2016-09-07 |
2023-05-02 |
阿堤亚制药公司 |
用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸
|
EP3538108A4
(fr)
*
|
2016-11-10 |
2020-06-17 |
Oyagen, Inc. |
Méthodes de traitement et d'inhibition d'une infection par le virus ebola
|
US20180193270A1
(en)
|
2016-11-29 |
2018-07-12 |
PureTech Health LLC |
Exosomes for delivery of therapeutic agents
|
JP6983814B2
(ja)
*
|
2016-12-14 |
2021-12-17 |
ヤマサ醤油株式会社 |
抗ウイルス活性を示すヌクレオシド誘導体
|
KR102592899B1
(ko)
|
2017-02-01 |
2023-10-24 |
아테아 파마슈티컬즈, 인크. |
C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
|
CN110869028B
(zh)
|
2017-03-14 |
2023-01-20 |
吉利德科学公司 |
治疗猫冠状病毒感染的方法
|
WO2018204198A1
(fr)
|
2017-05-01 |
2018-11-08 |
Gilead Sciences, Inc. |
Formes cristallines de (s) 2 éthylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)méthoxy)(phénoxy) phosphoryl)amino)propanoate
|
CN117982682A
(zh)
|
2017-07-11 |
2024-05-07 |
吉利德科学公司 |
用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
|
ES2969496T3
(es)
|
2017-08-01 |
2024-05-20 |
Gilead Sciences Inc |
Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
|
JP2020529409A
(ja)
|
2017-08-03 |
2020-10-08 |
大塚製薬株式会社 |
薬物化合物およびその精製方法
|
BR112020005177A2
(pt)
|
2017-09-18 |
2020-09-15 |
Janssen Biopharma, Inc. |
nucleosídeos, nucleotídeos e análogos dos mesmos substituídos
|
WO2019060692A1
(fr)
|
2017-09-21 |
2019-03-28 |
Chimerix, Inc. |
Formes morphiques de 4-amino-7-(3,4-dihydroxy-5-(hydroxyméthyle)tétrahydrofurane-2-yl)-2-méthyle-7 h-pyrrolo[2,3-d]pyrimidine-5-carboxamide et leurs utilisations
|
BR112020006780A2
(pt)
|
2017-10-05 |
2020-10-06 |
Glaxosmithkline Intellectual Property Development Limited |
moduladores do estimulador de genes do interferon (sting)
|
TW201927771A
(zh)
|
2017-10-05 |
2019-07-16 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
可作為蛋白質調節劑之雜環醯胺及其使用方法
|
CA3087932A1
(fr)
|
2018-01-09 |
2019-07-18 |
Ligand Pharmaceuticals, Inc. |
Composes acetal et leurs utilisations therapeutiques
|
US11897911B2
(en)
|
2018-03-07 |
2024-02-13 |
Sanofi |
Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same
|
CN112351799A
(zh)
|
2018-04-10 |
2021-02-09 |
阿堤亚制药公司 |
具有硬化的hcv感染患者的治疗
|
AU2019253023A1
(en)
|
2018-04-12 |
2020-11-12 |
Zogenix, Inc. |
Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
CA3122470A1
(fr)
|
2018-12-12 |
2020-06-18 |
Janssen Biopharma, Inc. |
Analogues nucleosidiques cyclobutyliques utilises comme anti-viraux
|
JP2022512397A
(ja)
|
2018-12-12 |
2022-02-03 |
ヤンセン バイオファーマ インク. |
抗ウイルス薬としてのシクロペンチルヌクレオシド類似体
|
JP2022533194A
(ja)
|
2019-05-16 |
2022-07-21 |
スティングセラ インコーポレイテッド |
ベンゾ[b][1,8]ナフチリジン酢酸誘導体および使用方法
|
WO2020232375A1
(fr)
|
2019-05-16 |
2020-11-19 |
Silicon Swat, Inc. |
Dérivés d'acide oxoacridinyle acétique et procédés d'utilisation
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
JP2022547888A
(ja)
|
2019-09-05 |
2022-11-16 |
サノフイ |
ヌクレオチド類似体を含有するオリゴヌクレオチド
|
JP2023512656A
(ja)
|
2020-01-27 |
2023-03-28 |
ギリアード サイエンシーズ, インコーポレイテッド |
SARS CoV-2感染を治療するための方法
|
US11738025B2
(en)
|
2020-02-04 |
2023-08-29 |
Oyagen, Inc. |
Method for treating coronavirus infections
|
US10874687B1
(en)
|
2020-02-27 |
2020-12-29 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against COVID-19
|
CA3169340A1
(fr)
|
2020-03-12 |
2021-09-16 |
Pavel R. Badalov |
Procedes de preparation de 1'-cyano nucleosides
|
AU2021251689B2
(en)
|
2020-04-06 |
2024-06-13 |
Gilead Sciences, Inc. |
Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
|
JP2023528810A
(ja)
|
2020-05-29 |
2023-07-06 |
ギリアード サイエンシーズ, インコーポレイテッド |
レムデシビル治療方法
|
JP2023531524A
(ja)
|
2020-06-24 |
2023-07-24 |
ギリアード サイエンシーズ, インコーポレイテッド |
1’-シアノヌクレオシド類似体及びその使用
|
DK4204421T3
(da)
|
2020-08-27 |
2024-05-27 |
Gilead Sciences Inc |
Forbindelser og fremgangsmåder til behandling af virale infektioner
|
CN116368146A
(zh)
|
2020-10-20 |
2023-06-30 |
赛诺菲 |
脱唾液酸糖蛋白受体的新型配体
|
CN112979735B
(zh)
*
|
2021-04-25 |
2021-09-17 |
南京颐媛生物医学研究院有限公司 |
抗肝炎病毒的化合物及其制备方法和应用
|
CN113278041B
(zh)
*
|
2021-07-16 |
2021-10-19 |
南京颐媛生物医学研究院有限公司 |
一种核苷磷酸酯及其合成方法与抗肝炎病毒的制药应用
|
US20230295172A1
(en)
|
2022-03-02 |
2023-09-21 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
CN115651047B
(zh)
*
|
2022-11-14 |
2023-03-17 |
天津奥瑞芙生物医药有限公司 |
2’-o-甲基核苷的制备方法
|
CN117362369B
(zh)
*
|
2023-10-09 |
2024-04-19 |
长沙晨辰医药科技有限公司 |
一锅法合成核苷二磷酸
|